Hyperlipidemia – Pipeline Review, H2 2012

Publisher Name :
Date: 31-Oct-2012
No. of pages: 93
Inquire Before Buying

Hyperlipidemia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Hyperlipidemia – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hyperlipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperlipidemia. Hyperlipidemia – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hyperlipidemia.
- A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hyperlipidemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Hyperlipidemia – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hyperlipidemia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Hyperlipidemia 10
Hyperlipidemia Therapeutics under Development by Companies 12
Hyperlipidemia Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Hyperlipidemia Therapeutics - Products under Development by Companies 19
Hyperlipidemia Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Hyperlipidemia Therapeutics Development 21
Samyang Corporation 21
Daewoong Pharmaceutical Co., Ltd. 22
Dr. Reddy's Laboratories Limited 23
Aegerion Pharmaceuticals, Inc. 24
Idera Pharmaceuticals, Inc. 25
Ligand Pharmaceuticals Incorporated 26
Medicure Inc. 27
Yuhan Corporation 28
WhanIn Pharmaceutical Co., Ltd. 29
Hanall Pharmaceutical Co., Ltd. 30
Ahn-Gook Pharmaceutical Co., Ltd. 31
Metabolex, Inc 32
aRigen Pharmaceuticals, Inc. 33
Esperion Therapeutics, Inc. 34
Hyperlipidemia - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
Metabasis drug for Diabetes And Hyperlipidemia - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
IMO-3100 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MBX-8025 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
IMD-5 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DRL-17822 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
HL040 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HL040 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ARMAK-105 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ETC-1002 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Atorvastatin + Aspirin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Simvastatin + Aspirin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
HL-037 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
HL-013 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Thyroid Receptor-beta Agonist Program - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MC-1 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
raltegravir - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
HL 007 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
HL 007 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
atorvastatin calcium - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HL053 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ARBs + Statins - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Drug For Hyperlipidemia - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Polypill - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 67
atorvastatin calcium - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
pterostilbene - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
JCH2 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
HCP0912 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
HCP1007 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
WIB-901H - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
AG-SAA010 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Hyperlipidemia Therapeutics - Drug Profile Updates 76
Hyperlipidemia Therapeutics - Discontinued Products 83
Hyperlipidemia Therapeutics - Dormant Products 84
Hyperlipidemia - Product Development Milestones 86
Featured News & Press Releases 86
Sep 28, 2012: Pronova And Takeda Announce New Drug Application Approval For Lotriga 2g In Japan For Treatment Of Hyperlipidemia 86
Aug 13, 2012: Ranbaxy Shifts Production Of Generic Lipitor To Mohali, India 86
Apr 27, 2012: Merck Wins US Zetia/Vytorin Patent Infringement Lawsuit 86
Apr 13, 2012: HanAll BioPharma Initiates Phase I And III Trials Of HL040 87
Mar 19, 2012: Pronova And Takeda Announce Results From Phase III Trial Of TAK-085 At Japanese Circulation Society 87
Jan 25, 2012: FDA Does Not Approve New Indications For ZETIA 88
Sep 29, 2011: Pronova And Takeda Announce Submission Of New Drug Application For TAK-085 In Japan For Treatment Of Hyperlipidemia 89
Jul 25, 2011: Daiichi Sankyo Receives FDA Approval For Welchol sNDA 89
Jul 18, 2011: Kowa And Lilly Report New Study Results Showing Minimal Potential For Drug Interaction Between LIVALO And Common Antiretroviral Therapy 90
Jun 23, 2011: Idera Pharmaceuticals Presents Mechanism Of Action Data Of IMO-3100 In Preclinical Model Of Arthritis At FOCIS 2011 Annual Meeting 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 93
Disclaimer 93

List of Tables
Number of Products Under Development for Hyperlipidemia, H2 2012 10
Products under Development for Hyperlipidemia - Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Samyang Corporation, H2 2012 21
Daewoong Pharmaceutical Co., Ltd., H2 2012 22
Dr. Reddy's Laboratories Limited, H2 2012 23
Aegerion Pharmaceuticals, Inc., H2 2012 24
Idera Pharmaceuticals, Inc., H2 2012 25
Ligand Pharmaceuticals Incorporated, H2 2012 26
Medicure Inc., H2 2012 27
Yuhan Corporation, H2 2012 28
WhanIn Pharmaceutical Co., Ltd., H2 2012 29
Hanall Pharmaceutical Co., Ltd., H2 2012 30
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 31
Metabolex, Inc, H2 2012 32
aRigen Pharmaceuticals, Inc., H2 2012 33
Esperion Therapeutics, Inc., H2 2012 34
Assessment by Monotherapy Products, H2 2012 35
Assessment by Combination Products, H2 2012 36
Assessment by Stage and Route of Administration, H2 2012 38
Assessment by Stage and Molecule Type, H2 2012 40
Hyperlipidemia Therapeutics - Drug Profile Updates 76
Hyperlipidemia Therapeutics - Discontinued Products 83
Hyperlipidemia Therapeutics - Dormant Products 84

List of Figures
Number of Products under Development for Hyperlipidemia, H2 2012 10
Products under Development for Hyperlipidemia - Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 35
Assessment by Combination Products, H2 2012 36
Assessment by Route of Administration, H2 2012 37
Assessment by Stage and Route of Administration, H2 2012 38
Assessment by Molecule Type, H2 2012 39
Assessment by Stage and Molecule Type, H2 2012 40

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Eculizumab – Comprehensive patent search
    Published: 16-Sep-2014        Price: US $9300 Onwards        
    Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world’s leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won’t need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on......
  • Venous Thromboembolism – Pipeline Review, H2 2014
    Published: 15-Sep-2014        Price: US $2000 Onwards        Pages: 86
    Global Markets Direct's, ‘Venous Thromboembolism Pipeline Review, H2 2014', provides an overview of the Venous Thromboembolism's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It a......
  • Paroxysmal Nocturnal Hemoglobinuria – Pipeline Review, H2 2014
    Published: 15-Sep-2014        Price: US $2000 Onwards        Pages: 65
    Global Markets Direct's, ‘Paroxysmal Nocturnal Hemoglobinuria Pipeline Review, H2 2014', provides an overview of the Paroxysmal Nocturnal Hemoglobinuria's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and......
  • Hemophilia B – Pipeline Review, H2 2014
    Published: 31-Aug-2014        Price: US $2000 Onwards        Pages: 96
    Global Markets Direct's, ‘Hemophilia B Pipeline Review, H2 2014', provides an overview of the Hemophilia B's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involv......
  • Thrombocytopenia – Pipeline Review, H2 2014
    Published: 31-Aug-2014        Price: US $2000 Onwards        Pages: 101
    Global Markets Direct's, ‘Thrombocytopenia Pipeline Review, H2 2014', provides an overview of the Thrombocytopenia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key pl......
  • Market Research Report on Global and Chinese Heparin (CAS 9005-49-6) Industry, 2009-2019
    Published: 3-Aug-2014        Price: US $2400 Onwards        Pages: 150
    Market Research Report on Global and Chinese Heparin Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Heparin industry. The report firstly reviews the basic information of Heparin including its classification, application and manufacturing technology; The report then explores global and China's top manufacturers of Heparin listing their product specification, capacity, Production value, and market share etc.; The report further analyzes quantitatively 20......
  • Hematology Deals and Alliances of 2013
    Published: 1-Aug-2014        Price: US $1495 Onwards        Pages: 200
    "Delivery of this report will take 1-3 days after purchase." The Hematology Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced ......
  • Hematology Partnering Terms and Agreements
    Published: 1-Aug-2014        Price: US $1995 Onwards        Pages: 630
    "Delivery of this report will take 1-3 days after purchase." The Hematology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the hematology partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in hematology partnering deals Average deal terms for headline, upfront and royalty by stage of development Hematology partnering agreement structure Hematology partnering contract documents Top......
  • Essential Thrombocythemia – Pipeline Review, H2 2014
    Published: 31-Jul-2014        Price: US $2000 Onwards        Pages: 86
    Global Markets Direct's, ‘Essential Thrombocythemia Pipeline Review, H2 2014', provides an overview of the Essential Thrombocythemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press relea......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs